Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine

Registry ID

EUCTR2015-005188-17

Source registry

EUCTR

Phase

PHASE4

Sponsor

Sanofi Pasteur SA

Last update

2026-08-16

Conditions

• Poliomyelitis

Summary

1) To demonstrate the non-inferiority of Inactivated Poliomyelitis Vaccine (IPV)-(Oral Poliomyelitis Vaccine) (OPV)-OPV (Sequential 1) and IPV-IPV-OPV (sequential 2) poliovirus vaccine administrations versus OPV-OPV-OPV (Reference) in terms of seroprotection rate 28 to 42 days after the third dose of the primary vaccination series.

Related clinical trials

• Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama
• Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine
• Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations
• Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh
• Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation
• A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

View on source registry